Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Clinical trial NCT02071862 · COMPLETED

Trial details

NCT number: NCT02071862
Sponsor: Calithera Biosciences, Inc
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors Triple-Negative Breast Cancer Non Small Cell Lung Cancer Renal Cell Carcinoma Mesothelioma Fumarate Hydratase (FH)-Deficient Tumors Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations Tumors Harboring Amplifications in the cMyc Gene

Start date: 2014-02-01
Primary completion: 2019-03-01
Enrollment: 210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.